Ramakrishnan et al. [34] analysed another strategy to target tumour antigens in addition to disrupting PD-1/PD-L1 interaction using bicistronic CAR-T (or dual CAR-T) cells targeting the two antigens CD19 and CD22 (AUTO3), followed by consolidation with anti-PD-1 (three doses of pembrolizumab 200 mg) in 33 patients with R/R DLBCL with a median number of previous lines of treatment of three (1–10). The gene discussed is PDCD1; the disease is neoplasm.